Valion Bio VBIO Ratios (2021-2026)

NASDAQ VBIO
$2.20 -0.20 (-8.33%)
At close: Sep 10, 2026 · 4:00 PM EDT
Reported Financials

Valion Bio Quarterly Ratios

Periods 21 quarters
Latest Jun 2026

Valion Bio reported a gross margin of -115.38% for the quarter ended Jun 2026. These financial ratios cover 21 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Profitability
Gross Margin
-12.31%-9.39%-0.51%16.36%23.67%13.21%10.54%30.05%37.89%38.30%1.40%50.00%21.43%34.92%-132.78%71.43%62.79%-99.32%91.25%-115.38%
EBT Margin
-476.87%-443.68%-589.20%-523.60%-571.59%-541.72%-552.94%-562.77%-1,319.88%-624.11%-628.57%-443.41%-947.14%-1,135.71%-823.89%-2,151.43%-2,248.84%-1,697.95%
EBIT Margin
-393.66%-443.68%-589.20%-523.60%-571.59%-541.72%-552.94%-562.77%-1,319.88%-624.11%-628.57%-443.41%-904.29%-1,135.71%-823.89%-2,151.43%-2,248.84%-1,700.68%
EBITDA Margin
-393.66%-443.68%-589.20%-523.60%-571.59%-541.72%-552.94%-562.77%-1,319.88%-624.11%-628.57%-443.41%-904.29%-1,135.71%-823.89%-2,151.43%-2,248.84%-1,700.68%
Operating Margin
-393.66%-443.68%-589.20%-523.60%-571.59%-541.72%-552.94%-562.77%-1,319.88%-624.11%-628.57%-443.41%-904.29%-1,135.71%-823.89%-2,151.43%-2,248.84%-1,700.68%
Net Margin
-476.87%-443.68%-589.20%-523.36%-571.59%-541.72%-552.94%-562.77%-1,319.88%-624.11%-628.57%-443.41%-947.14%-1,135.71%-823.89%-2,151.43%-2,248.84%-1,697.95%
FCF Margin
-202.61%-593.50%-709.51%-515.42%-325.76%-583.86%-543.87%-670.21%-1,551.55%-651.42%-496.92%-508.98%-928.57%-1,111.11%-736.11%-1,285.71%-2,111.63%-1,373.97%-2,891.25%
Efficiency
Inventory AverageInventory Avg.
0.44M0.64M0.80M0.81M0.90M0.97M0.96M0.86M0.80M0.80M0.77M0.69M0.65M0.63M0.60M0.38M0.47M
Assets AverageAssets Avg.
13.87M11.86M9.62M7.04M6.49M5.85M5.80M6.08M4.22M4.03M4.09M3.10M3.29M4.14M5.37M18.92M32.04M
Invested CapitalInvested Cap.
4.08M
Asset Utilization RatioAsset Util.
0.100.140.190.260.280.240.210.190.270.280.230.250.160.110.090.020.01
Leverage & Solvency
Interest Coverage RatioInterest Cover
-4.73-21.10
Debt Ratio
0.08
Times Interest Earned
-4.73-21.10
Valuation
Price to EarningsP/E
-402.12-474.80-422.73-3.69-1.87-0.97-1.01-0.80-0.43-0.85-0.80-0.74-0.05-0.05-0.08-0.06
Price to SalesP/S
0.00M0.00M0.00M20.0010.325.4813.274.962.723.757.608.410.381.031.861.050.841.80
Price to BookP/B
69.4495.88155.831.651.160.400.680.240.270.580.250.370.030.020.040.040.000.02
Enterprise Value
908.69M1,052.76M1,266.76M3.21M0.69M-3.14M-0.56M-3.80M-2.42M-0.45M-2.64M-1.14M-1.93M-0.63M-1.02M-3.35M-12.58M-2.13M
EV to EBIT
-396.46-469.77-419.73-1.24-0.311.480.262.161.080.302.080.801.300.420.531.35
EV to EBITDA
-396.46-469.77-419.73-1.24-0.311.480.262.161.080.302.080.801.300.420.531.35
Market Capitalization
921.67M1,063.56M1,275.81M9.54M4.21M2.06M2.14M1.40M0.97M1.25M1.06M1.06M0.07M0.07M0.16M0.15M0.07M0.07M
Price to FCFP/FCF
-333.94-482.12-741.75-3.43-1.90-0.82-0.86-0.76-0.55-0.74-0.82-0.76-0.05-0.08-0.09-0.08-0.03
EV to FCF
-329.24-477.22-736.49-1.15-0.311.250.232.071.370.262.030.811.460.700.561.675.44
EV to CFO
-329.24-478.53-736.49-1.16-0.311.290.232.071.370.262.030.811.460.700.561.685.50
Return Ratios
Return on Sales [ROS]ROS
-393.66%-443.68%-589.20%-523.60%-571.59%-541.72%-552.94%-562.77%-1,319.88%-624.11%-628.57%-443.41%-904.29%-1,135.71%-823.89%-2,151.43%-2,248.84%-1,700.68%
Return on Capital Employed [ROCE]ROCE
-53.39%-92.60%-133.46%-195.58%-202.93%-193.69%-171.97%-176.14%-235.64%-196.05%-182.00%-200.14%-222.89%-191.30%-156.56%
Return on Assets [ROA]ROA
-50.78%-74.03%-105.39%-143.42%-153.73%-155.27%-142.33%-135.56%-180.27%-168.82%-158.54%-184.52%-174.54%-153.39%-137.88%